Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Impact · against what's priced in

Argenx's acquisition of Unnatural Products is a marginal catalyst as it adds a new early-stage asset to a pipeline that the market is already discounting. While it expands the portfolio, the heavy reliance on contingent value rights (CVRs) for $600 million of the deal value limits the immediate impact on enterprise value.

ARGX+0.10

Not in the price yet

In context

The acquisition of UNP for $550 million upfront is a new pipeline expansion not previously mentioned in the market's assumptions, though the total $1.15 billion potential cost is mitigated by milestone-based payouts.